Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?
Journal Title: OncoReview - Year 2014, Vol 4, Issue 2
Abstract
Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmacological treatment. In a group of patients, however, systolic cardiac function does not fully recover. The reasons of this unfavorable prognosis are subject of heated discussion.
Authors and Affiliations
Sebastian Szmit, Łukasz Kownacki, Adam Torbicki
Keywords
Related Articles
- EP ID EP67753
- DOI -
- Views 189
- Downloads 0
Percutaneous retrieval of a fractured portacath fragment in two patients undergoing long-term chemotherapy
The paper discusses two clinical cases of cancer patients undergoing chemotherapy, in whom fractured and displaced tips of portacath catheters were revealed based on plain chest imaging. In the first case, the portacath...
Meeting the human
We often have to deal with problems which force us to making difficult choices and decisions that have not only clinical aspects but also ethical during the oncologist’s work. Unfortunately there is not enough place in a...
Targeted therapies in neuroendocrine neoplasms
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biologica...
Octreotide LAR in neuroendocrine tumors - a summary of the experience
Neuroendocrine tumors are a rare and heterogeneous group of neoplasms. Most of the patient is diagnosed with locally advanced or metastatic disease and curative surgery is rarely an option. Somatostatin analogues have b...
The cardiac safety during treatment with sunitinib and sorafenib, multikinase angiogenesis inhibitors
Cardiotoxicity of multikinase angiogenesis inhibitors, sunitinib and sorafenib, is most often myocardial systolic dysfunction or arterial and venous thromboembolic events. Essential risk factor seems to be iatrogenic art...